Alphonse Rudakubana, 49, said his family expected a 'high degree of confidentiality' and did not want those 'in charge of ...

Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats.

CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.